Genfit (Genfit) Beta : 1.02 (As of May. 25, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Genfit Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-05-25), Genfit's Beta is 1.02.

Genfit Beta Historical Data

The historical data trend for Genfit's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genfit Beta Chart

Genfit Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beta

Get a 7-Day Free Trial

1.40

0.99

Genfit Quarterly Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Beta	Get a 7-Day Free Trial															1.64	1.40	1.40	1.53	0.99

Competitive Comparison of Genfit's Beta

For the Biotechnology subindustry, Genfit's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genfit's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genfit's Beta distribution charts can be found below:

* The bar in red indicates where Genfit's Beta falls into.

Genfit Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Genfit (NAS:GNFT) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Genfit Beta Related Terms

Thank you for viewing the detailed overview of Genfit's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.

Genfit (Genfit) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genfit SA (NAS:GNFT) » Definitions » Beta

Comparable Companies

Traded in Other Exchanges

GNFTF:USA 0QT6:UK GNFT:France XUPB:Germany

Address

Parc Eurasante, 885, Avenue Eugene Avinee, Loos, FRA, 59120

Website

https://www.genfit.com

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. The company conducts clinical trials in a variety of European and North American countries when advancing through stages of development. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.